Ovid Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary

Ovid Therapeutics

13/08/2026 14:31

Ovid Therapeutics Inc. OVID.OQ reported a quarterly adjusted loss of 8 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -6 cents.  The mean expectation of ten analysts for the quarter was for a loss of 12 cents per share. Wall Street expected results to range from -20 cents to -9 cents per share.
Revenue fell 88.3% to $733.00 thousand from a year ago; analysts expected zero. 
Ovid Therapeutics Inc.'s reported EPS for the quarter was a loss of 8 cents​.
The company reported a quarterly loss of $15.01 million.
Ovid Therapeutics Inc. shares had fallen by 2.6% this quarter and gained 60.7% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 7.1% in the last three months.​ 
In the last 30 days, one analyst negatively revised an earnings estimate
RECOMMENDATIONS
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 10 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is  "buy."
Wall Street's median 12-month price target for Ovid Therapeutics Inc. is $5.00, about 47.6% above its last closing price of $2.62
This summary was machine generated from LSEG data August 13 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.12
-0.08
Beat
Mar. 31 2026 
-0.12
-0.12
Met
Dec. 31 2025 
-0.12
0.06
Beat
Sep. 30 2025 
-0.15
-0.17
Missed